Morgan L. Maeder, PhD

Third Rock Ventures NewCo, Scientist

What is your current professional status?


What is your work setting?


What is your scientific area of research?

Gene editing and gene therapy

Why do you want to be a mentor?

To share my experiences and the pros and cons of the career path I have taken in an effort to help junior scientists consider what options are available and what next steps make the most sense for them.

As a mentor, what are you hoping to gain from this experience?

I hope to be able to provide some helpful insight into career paths but, potentially more importantly, some reassurance that there is rarely a wrong choice and that if you follow your gut and pursue good science that excites you, you are making the right decision.  I look forward to connecting and forming relationships with members of the gene therapy community.

How important are the following in the selection of a mentee?
(1 – 5 scale, 1 = most important, 5 = least important)

  • Compatibility of Scientific Specialties: 3
  • Geographic Location: 4
  • Professional Status / Success: 5
  • Compatibility of Career Path: 1 (most)
  • Communication Style: 2 (most)

Summarize in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy.

Morgan Maeder has over a decade of experience in the field of Gene Editing. She obtained her PhD from Harvard University in the lab of J. Keith Joung where she worked with zinc finger nucleases, TALENs and CRISPR/Cas9. During her graduate work she focused on the development of tools for targeted epigenomic modifications, such as gene activation and repression, and DNA demethylation. In 2013, she joined Editas Medicine as the first Scientist. At Editas, she led the development of a CRISPR/Cas9-based gene editing approach to target the CEP290 gene for treatment of Leber Congenital Amaurosis type 10. Morgan is currently working with Third Rock Ventures to launch a new startup company.

View CV


23rd Annual Meeting

May 12-15 | Boston